Abbott to acquire Exact Sciences for $21 billion
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Jaypirca is making waves in the fight against B-cell malignancies
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated